Company profile for Iambic Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Lambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinics with unprecedented spee...
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Lambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinics with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5627 Oberlin Drive, Suite 120 San Diego, CA 92121
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/busy-ai-driven-iambic-therapeutics-raises-over-100m-oversubscribed-funding-round

FIERCE BIOTECH
10 Nov 2025

https://www.businesswire.com/news/home/20251104266121/en/Iambic-to-Participate-in-November-Investor-Conferences

BUSINESS WIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251021091520/en/Iambic-Announces-Research-Collaboration-with-Jazz-Pharmaceuticals-for-IAM1363-and-Zanidatamab-Combination-Cohort-in-HER2-Positive-Breast-Cancer

BUSINESSWIRE
21 Oct 2025

https://www.businesswire.com/news/home/20251020414237/en/Iambic-Shares-Clinical-Data-from-Ph11B-Study-of-IAM1363-a-Highly-Selective-Type-2-HER2-Inhibitor-Demonstrating-Monotherapy-Activity-in-Heavily-Pretreated-Patients-with-HER2-Alterations-at-the-2025-ESMO-Congress

BUSINESSWIRE
20 Oct 2025

https://www.businesswire.com/news/home/20251001729712/en/Iambic-Therapeutics-Announces-the-Addition-of-Shalini-Sharp-to-its-Board-of-Directors

BUSINESSWIRE
01 Oct 2025

https://www.businesswire.com/news/home/20250903621032/en/Iambic-to-Present-New-Pre-Clinical-NSCLC-Data-for-IAM1363-a-Selective-Type-II-Inhibitor-for-HER2-Cancers-at-the-2025-World-Conference-on-Lung-Cancer

BUSINESSWIRE
03 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty